As of 2025-09-15, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 13.0x | 10.8x |
| Forward P/E multiples | 11.8x - 19.2x | 15.5x |
| Fair Price | (37.51) - (41.57) | (41.99) |
| Upside | -118.8% - -120.8% | -121.0% |
| Date | EV/EBITDA |